BioSpace News Archive

Astria Therapeutics, Inc. today announced that it will share new STAR-0215 data in two poster presentations at the upcoming American Academy of Allergy, Asthma, and Immunology Annual Meeting in San Antonio, Texas on February 26, 2023 at 9:45am CST.

Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO ® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis.

Donaldson Company, Inc. announced the acquisition of Isolere Bio, Inc., an early-stage biotechnology company that develops novel and proprietary IsoTag™ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.

Standard BioTools Inc. announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 20, 2023, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan, as a material inducement to four individuals entering into employment with Standard BioTools™.

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) reiterates the strategic prioritization of its pipeline of proprietary oncology drugs, defined as Next Generation Chemotherapies (NGCs).

Vaxcyte, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s infant Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).

Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) and alopecia.

PreciseDx today announced the appointment of Bradley Gendell as Chief Financial Officer.

Legend Biotech Corporation announced that it received notice from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) on February 17, 2023 indicating that the Company has regained compliance with Nasdaq Listing Rules 5250(c)(2).

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) further to the Company’s announcement dated January 26, 2023 that it had entered into a binding agreement (the “Definitive Agreement”) to acquire Siva Therapeutics, Inc. (“Siva”), the developer of Targeted Hyperthermia Therapy photo thermal therapy for cancer tumors using Sona’s uniquely biocompatible gold nanorods (the “Proposed Transaction”).